We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-1.07%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$203M
AUM Growth
+$1.2M
(+0.6%)
Cap. Flow
+$4.13M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
50.42%
Holding
59
New
11
Increased
16
Reduced
17
Closed
14
Top Buys
| 1 |
Cue Biopharma
CUE
|
+$7.68M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$7.29M |
| 3 |
Baxter International
BAX
|
+$6.69M |
| 4 |
Prothena Corp
PRTA
|
+$6.56M |
| 5 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$5.31M |
Top Sells
| 1 |
Kura Oncology
KURA
|
+$12.8M |
| 2 |
Arrowhead Research
ARWR
|
+$4.93M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.28M |
| 4 |
Aldeyra Therapeutics
ALDX
|
+$3.41M |
| 5 |
Vericel Corp
VCEL
|
+$2.9M |
Sector Composition
| 1 | Healthcare | 92.16% |
| 2 | Technology | 4.47% |
| 3 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Kura Oncology
KURA
$1.01B
| $3.29M | 1.62% |
107,367
-577,633
| -84% | -$12.8M |
|
|
ZGNX
27
DELISTED
Zogenix, Inc.
ZGNX
| $3.24M | 1.6% |
180,924
+34,578
| +24% | +$847K |
|
28
Organogenesis Holdings
ORGO
$320M
| $2.6M | 1.28% |
676,553
+140,937
| +26% | +$557K |
|
|
TVRD
29
Tvardi Therapeutics
TVRD
$27.5M
| $2.22M | 1.1% |
4,851
+2,435
| +101% | +$1.41M |
|
30
Amneal Pharmaceuticals
AMRX
$5.49B
| $1.99M | 0.98% |
+512,659
| New | +$2.19M |
|
|
ONEM
31
DELISTED
1Life Healthcare
ONEM
| $1.86M | 0.92% |
+65,778
| New | +$2.08M |
|
|
KZR
32
DELISTED
Kezar Life Sciences
KZR
| $1.77M | 0.87% |
+36,598
| New | +$1.75M |
|
33
Dianthus Therapeutics
DNTH
$5.46B
| $1.66M | 0.82% |
15,266
+4,730
| +45% | +$560K |
|
34
QuidelOrtho
QDEL
$1.24B
| $1.65M | 0.81% |
+7,500
| New | +$1.67M |
|
35
Establishment Labs
ESTA
$2.67B
| $1.59M | 0.79% |
86,042
-41,131
| -32% | -$732K |
|
36
Gyre Therapeutics
GYRE
$731M
| $1.3M | 0.64% |
40,224
+7,151
| +22% | +$280K |
|
37
BioXcel Therapeutics
BTAI
$28.5M
| $1.29M | 0.64% |
+1,863
| New | +$1.4M |
|
38
ADMA Biologics
ADMA
$2.01B
| $1.28M | 0.63% |
535,324
-763,976
| -59% | -$2.09M |
|
|
KRTX
39
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $1.22M | 0.6% |
+15,826
| New | +$1.35M |
|
40
Immatics
IMTX
$1.29B
| $1.2M | 0.59% |
+113,460
| New | +$1.19M |
|
41
Neurogene
NGNE
$787M
| $797K | 0.39% |
+3,319
| New | +$804K |
|
|
EVFM
42
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $590K | 0.29% |
16,667
-10,852
| -39% | -$472K |
|
|
APEN
43
DELISTED
Apollo Endosurgery, Inc.
APEN
| $469K | 0.23% |
277,590
-102,355
| -27% | -$154K |
|
44
OrthoPediatrics
KIDS
$507M
| $386K | 0.19% |
+8,399
| New | +$390K |
|
|
MITO
45
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
| $346K | 0.17% |
256,044
-35,100
| -12% | -$60.1K |
|
|
BEAT
46
DELISTED
BioTelemetry, Inc.
BEAT
| $274K | 0.14% |
6,000
-18,733
| -76% | -$783K |
|
|
RETA
47
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $156K | 0.08% |
+1,600
| New | +$200K |
|
48
AMN Healthcare
AMN
$1.25B
| – | – |
-26,851
| Closed | -$1.22M |
|
|
49
Arrowhead Research
ARWR
$10.1B
| – | – |
-114,100
| Closed | -$4.93M |
|
50
CALL
Bristol-Myers Squibb
BMY
$120B
| – | – |
-50,000
| Closed | -$2.94M |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA